GFAP (human) ELISA Kit

Glial Fibrillary Acidic Protein (GFAP), is the principal 8-9 nm intermediate filament in mature astrocytes of the Central Nervous System (CNS). The findings showed that GFAP is released after traumatic brain injury severity and outcome into the blood very soon after traumatic brain injury (TBI), and that GFAP is not released after multiple trauma without brain injury. In the CNS following injury, either as a result of trauma, disease, genetic disorders, or chemical insult, astrocytes become reactive and respond in astrogliosis. Astrogliosis is characterized by rapid synthesis of GFAP. GFAP normally increases with age and there is a wide variation in the collection and processing of human brain tissue. GFAP is also an established biomarker of retinal stress. Enzyme ImmunoAssay (EIA) is a technique to detect and quantify antigens (proteins, hormones�) or antibodies in samples. It relies on the ability of an antibody to bind a specific antigen. Either the antibody or the antigen is labelled with an enzyme whose substrate is a chromogen or a fluorogen converted in a measurable product (color or fluorescence). Enzyme-linked Immunosorbent Assay (ELISA) is a type of EIA using a solid phase (ex: microtiter plate) coated with an antigen immobilizing the molecule to detect. Over the time, scientists have extended the term ELISA to EIAs using an antibody coating the solid phase. That explains why our EIA kits using coated antibodies are also called ELISA kits.